Alnylam Pharmaceuticals (ALNY) has initiated a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease). The Phase 1/2 trial will be conducted initially in normal healthy volunteers, and, then, in patients with alpha-1 liver disease. Initiation of this trial is based on “encouraging” pre-clinical data recently presented at the Digestive Disease Week meeting, Alnylam said.
“We believe ALN-AAT has the potential to be a transformative therapy for patients with alpha-1 liver disease, an increasingly recognized clinical manifestation of alpha-1 antitrypsin deficiency where liver transplantation is the only available treatment option,” said Akshay Vaishnaw, chief medical officer of Alnylam. The biopharmaceutical company expects to present initial clinical data from the new trial in early 2016.
There are 7 research firms in total that have issued ratings on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) within the past year. The consensus, or mean target price of the Wall Street analysts covering the firm is $147.142.
Analysts are predicting that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will report $-0.74 earnings per share when they next issue their quarterly earnings release on or around 2015-08-06. The consensus mean estimate is the calculated mean of all brokerage sell-side analysts that issue earnings estimates for the company. In the most recent quarter the company reported earnings of $-0.62 that ended on 2015-03-31.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has a 1.33 consensus analyst rating on the stock based on an arithmetical average of the 7 ratings given by the brokerage analysts covering the company. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell. The highest estimate of the 7 covering analysts sees the stock climbing to $180 within the next year while the lowest estimate places the 12-month target price at $125.
Alnylam Pharmaceuticals, Inc. (Alnylam) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). Its Alnylam 5×15, is focused on the development and commercialization of novel RNAi therapeutics for the treatment of genetically defined diseases. Its core programs in clinical or pre-clinical development are: ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR); ALN-APC for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN for the treatment of refractory anemia, and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The Company has three partner-based programs in clinical or pre-clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV), infection, ALN-VSP for the treatment of liver cancers and ALN-HTT for the treatment of Huntington’s disease (HD).